Target Name: MIR937
NCBI ID: G100126338
Review Report on MIR937 Target / Biomarker Content of Review Report on MIR937 Target / Biomarker
Other Name(s): hsa-miR-937-5p | MicroRNA 937 | microRNA 937 | hsa-mir-937 | hsa-miR-937-3p | MIRN937 | mir-937

Introduction to MIR937, A Potential Drug Target

MIR937, a small non-coding RNA molecule, has gained increasing attention in the field of biomedical research as a potential drug target or biomarker. This article delves into the significance of MIR937 and its potential implications in therapeutic interventions and diagnosis.

The Discovery of MIR937

MIR937 was originally discovered as a differentially expressed microRNA during studies investigating the role of non-coding RNA molecules in various diseases. Non-coding RNAs are a class of RNA molecules that do not code for proteins but instead regulate gene expression. This discovery sparked interest due to the observed dysregulation of MIR937 in several diseases, suggesting its potential role as a therapeutic target or biomarker.

MIR937 as a Drug Target

As a small non-coding RNA, MIR937 exerts its influence by binding to messenger RNAs (mRNAs) and inhibiting their translation into proteins. This regulatory function makes it an attractive candidate as a drug target. By designing molecules that can specifically bind to and inhibit MIR937, it may be possible to restore normal gene expression and alleviate disease symptoms.

Several studies have explored the potential of MIR937 inhibition for therapeutic purposes. For example, in cancer research, MIR937 has been shown to promote tumor growth and metastasis by suppressing the expression of tumor suppressor genes. By targeting MIR937, it may be possible to halt or reduce tumor progression, providing a new avenue for cancer treatment.

Moreover, MIR937 has also been implicated in neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Research has suggested that MIR937 may be involved in the regulation of key processes contributing to neurodegeneration. Inhibition of MIR937 has shown promise in experimental models, leading to the exploration of its potential as a therapeutic target for these debilitating diseases.

MIR937 as a Biomarker

In addition to its potential as a drug target, MIR937 also holds promise as a biomarker for various diseases. Biomarkers are measurable indicators that provide valuable diagnostic or prognostic information about a particular condition or disease.

Several studies have reported dysregulated levels of MIR937 in different diseases, making it a potential candidate for diagnostic or prognostic purposes. For example, in cardiovascular diseases, altered expression of MIR937 has been observed in patients with heart failure, suggesting its potential as a biomarker for disease progression or severity.

Furthermore, MIR937 has shown promise as a biomarker for cancer. Its dysregulation in various cancer types, along with its involvement in tumor growth and metastasis, makes it a potential diagnostic tool for early detection or monitoring the response to treatment.

Challenges and Future Directions

While MIR937 holds great promise as a drug target or biomarker, numerous challenges need to be addressed for its successful translation into clinical applications. One major hurdle is the development of delivery systems that can effectively deliver therapeutic agents specifically targeting MIR937 to the desired tissues or cells. This is particularly crucial as off-target effects can cause unintended consequences.

Moreover, the development of reliable and sensitive detection methods is essential for the utilization of MIR937 as a biomarker. Techniques such as quantitative polymerase chain reaction (qPCR) and next-generation sequencing have shown potential for measuring microRNA levels, but further refinement and validation are necessary.


In summary, MIR937 represents a novel and exciting avenue in the fields of drug development and diagnostics. Its dysregulation in various diseases suggests its potential as both a therapeutic target and biomarker. Further research and validation of its role in specific diseases will be crucial in harnessing the full potential of MIR937 for improving patient outcomes.

Protein Name: MicroRNA 937

The "MIR937 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR937 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

MIR938 | MIR939 | MIR940 | MIR941-1 | MIR941-2 | MIR941-3 | MIR941-4 | MIR942 | MIR943 | MIR944 | MIS18A | MIS18A-AS1 | MISFA | MKLN1-AS | MKNK1-AS1 | MKRN2OS | MLF1-DT | MLIP-AS1 | MLKL | MMAA | MMP21 | MMP24OS | MMP25-AS1 | MMP9 | MNX1 | MORF4L1P7 | MORN4 | MOV10L1 | MOXD2P | MPDU1-AS1 | MPHOSPH8 | MPZL3 | MRGPRX2 | MRGPRX3 | MRGPRX4 | MRLN | MROH7-TTC4 | MRPL23-AS1 | MRPL39 | MRPL50 | MRPS18CP7 | MRPS21 | MRPS30-DT | MRPS31P4 | MRPS31P5 | MSC-AS1 | MSH5-SAPCD1 | MSRB3-AS1 | MSS51 | MSTO2P | MTA1-DT | MTMR12 | MTND1P11 | MTND1P23 | MTND1P3 | MTND1P33 | MTND2P21 | MTND2P28 | MTND4P10 | MTND4P12 | MTND4P17 | MTND4P22 | MTND4P24 | MTND4P28 | MTND4P29 | MTND5P16 | MTND5P19 | MTND5P20 | MTND5P31 | MTND5P8 | MTOR | MTRF1L | MTRF1LP2 | MTRNR2L1 | MTRNR2L10 | MTRNR2L11 | MTRNR2L12 | MTRNR2L13 | MTRNR2L2 | MTRNR2L3 | MTRNR2L4 | MTRNR2L5 | MTRNR2L6 | MTRNR2L7 | MTRNR2L8 | MTRNR2L9 | MTUS2-AS1 | MUC12 | MUC22 | MUC8 | MUCL1 | MUPP | MXRA8 | MYC | MYCBP2-AS1 | MYHAS | MYLK-AS1 | MYLK-AS2 | MYO16-AS1 | MYO16-AS2